Karat Packaging Inc. Announces Pricing of Secondary Offering of Common Stock
CHINO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Karat Packaging Inc. (Nasdaq: KRT) ('Karat' or the 'Company'), a specialty distributor and manufacturer of disposable foodservice products and related items, today announced the pricing of its previously announced underwritten secondary offering of 1,500,000 shares of Karat's common stock by certain members of the Company's management team (collectively, the 'Selling Stockholders') at a price of $27.00 per share. The underwriters have been granted a 30-day option to purchase up to an additional 225,000 shares of Karat's common stock from the Selling Stockholders. The offering is expected to close on June 12, 2025, subject to the satisfaction of customary closing conditions. The Company will not receive any proceeds from the sale of shares by the Selling Stockholders.
BofA Securities and William Blair & Company, L.L.C. are acting as the joint lead book-runners for the offering.
The offering of these securities is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-286011), which was filed with the U.S. Securities and Exchange Commission (the 'SEC') on March 21, 2025 and declared effective on March 28, 2025. The offering is being made only by means of a prospectus supplement and an accompanying prospectus as filed with the SEC. A copy of the prospectus and prospectus supplement related to the offering may be obtained, when available, by visiting the SEC's website at www.sec.gov. Alternatively, copies of the prospectus and prospectus supplement relating to the offering may be obtained by contacting BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001, or by e-mail at dg.prospectus_requests@bofa.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling (800) 621-0687, or emailing prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Karat Packaging Inc.
Karat Packaging Inc. is a specialty distributor and manufacturer of a wide range of disposable foodservice products and related items, primarily used by national and regional restaurants and in foodservice settings throughout the United States. Its products include food and take-out containers, bags, tableware, cups, lids, cutlery, straws, specialty beverage ingredients, equipment, gloves and other products. The Company's eco-friendly Karat Earth® line offers quality, sustainably-focused products that are made from renewable resources. Karat Packaging also offers customized solutions, including new product development and design, printing, and logistics services.
Forward Looking Statements
Statements made in this release that are not statements of historical or current facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the proposed offering. We caution readers that forward-looking statements are predictions based on our current expectations about future events, and are subject to risks and uncertainties. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC, including the prospectus supplement filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with this offering. The forward-looking statements included in this press release are made only as of the date hereof and are expressly qualified in their entirety by these cautionary statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law.
Investor Relations and Media Contact
PondelWilkinson Inc.Judy Lin or Roger Pondel310-279-5980IR@karatpackaging.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Gene Therapy Collaboration and Licensing Deals Report and Directory 2025: Explore the Financials Behind 787 Gene Therapy Licensing Deals from 2016-2025
The Gene Therapy Collaboration and Licencing Deals report features 787 deals with financial terms and SEC contracts. Explore trends in R&D partnerships, commercialization strategies, and IP structures. Ideal for benchmarking deal terms, assessing opportunities, and streamlining due diligence in the gene therapy space. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" report has been added to report contains a comprehensive listing of 787 gene therapy deals announced since 2016, including financial terms where available, and links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the world's leading biopharma revised and updated, the report provides details of gene therapy deals from 2016 to report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of report includes collaboration, development, research and licensing initial chapters of this report provide an orientation of gene therapy dealmaking. Chapter 1 introduces the report, while Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016. Chapter 3 offers a summary of the leading gene therapy deals since 2016, listed by headline value. Chapter 4 lists the top 25 most active companies in gene therapy dealmaking, with summaries and comprehensive listings of deals. Chapter 5 and Chapter 6 offer detailed reviews of gene therapy deals and partnering deals announced since Jan 2016, focusing on contract documents in the public domain and specific gene therapy technologies report also includes numerous tables and figures that illustrate the trends and activities in gene therapy deal making since 2016. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on Therapy Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse gene therapy collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeGene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies Therapy Collaboration and Licensing Deals includes: Trends in gene therapy dealmaking in the biopharma industry Directory of gene therapy deal records covering pharmaceutical and biotechnology The leading gene therapy deals by value Most active gene therapy licensing dealmakers Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered:Chapter 1 - IntroductionChapter 2 - Trends in gene therapy dealmaking2.1. Introduction2.2. Gene therapy deals over the years2.3. Most active gene therapy dealmakers2.4. Gene therapy deals by deal type2.5. Gene therapy deals by therapy area2.6. Gene therapy deals by industry sector2.7. Deal terms for gene therapy deals2.7.1 Gene therapy deals headline values2.7.2 Gene therapy deal upfront payments2.7.3 Gene therapy deal milestone payments2.7.4 Gene therapy royalty ratesChapter 3 - Leading gene therapy deals3.1. Introduction3.2. Top gene therapy deals by valueChapter 4 - Most active gene therapy dealmakers4.1. Introduction4.2. Most active gene therapy dealmakers4.3. Most active gene therapy deals company profilesChapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directoryChapter 6 - Gene therapy dealmaking by technology typeDeal directory Deal directory - Gene therapy deals by company A-Z Deal directory - Gene therapy deals by deal type Deal directory - Gene therapy deals by therapy area For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
29 minutes ago
- Yahoo
Karooooo Ltd. Announces Pricing of Secondary Public Offering of Ordinary Shares
SINGAPORE, June 12, 2025--(BUSINESS WIRE)--Karooooo Ltd. ("Karooooo") announced the pricing of an underwritten secondary public offering (the "Offering") of 1,500,000 ordinary shares held by Isaias (Zak) Jose Calisto, Karooooo's chief executive officer (the "Selling Shareholder"), at a price to the public of $50.00 per ordinary share (the "public offering price") for total gross proceeds of approximately $75.0 million. The Offering is expected to close on June 13, 2025, subject to customary closing conditions. In addition, the underwriters of the Offering will have a 30-day option to purchase up to an additional 225,000 ordinary shares from the Selling Shareholder at the public offering price. Karooooo's ordinary shares are listed on the Nasdaq Capital Market under the symbol "KARO." Karooooo is not selling any ordinary shares in the Offering and will not receive any of the proceeds from the sale of any ordinary shares by the Selling Shareholder, but will bear the costs associated with the sale of such shares, other than any underwriting commissions, which will be borne by the Selling Shareholder. Following completion of the Offering, the Selling Shareholder will continue to beneficially own 17,917,958 ordinary shares, or 58.00% (or 17,692,958 ordinary shares, or 57.27% if the option to purchase additional shares is exercised in full) of the 30,893,300 ordinary shares issued and outstanding. In addition, Juan Marais, the Chief Sales Officer of Karooooo, is the beneficial owner of 3,250,793 ordinary shares, or 10.52% of the issued and outstanding shares of Karooooo, through One Spire (Pty) Ltd. ("One Spire"). The Selling Shareholder and One Spire have agreed that if the Selling Shareholder's beneficial ownership falls to below 51% of the issued and outstanding shares of Karooooo, then One Spire will cast all votes in respect of the ordinary shares that One Spire beneficially owns as directed by the Selling Shareholder. UBS Investment Bank, William Blair and Standard Bank are acting as joint active lead book-running managers for the Offering. Raymond James is acting as a joint book-running manager for the Offering. Needham & Company is acting as lead manager. Roth Capital Partners is acting as a co-manager for the Offering. The Registration Statement on Form F-3 relating to these securities has been filed with the Securities and Exchange Commission (the "SEC") and was declared effective by the SEC on July 22, 2024. The Offering is being made only by means of a prospectus and an accompanying prospectus supplement. Before investing, prospective investors should read the prospectus, any accompanying prospectus supplement related to the Offering and the documents incorporated by reference therein for more complete information. Copies of these documents, including the final prospectus supplement, when available, may be obtained at no charge on the SEC's website at Alternatively, copies of the preliminary prospectus supplement, the final prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting UBS Securities LLC at 1285 6th Ave, New York, NY 10019, William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@ or The Standard Bank of South Africa Limited at 30 Baker Street, Rosebank, Johannesburg, South Africa 2196 or by telephone at +27 (0)11 344 5725. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Karooooo Karooooo digitally transforms physical operations by simplifying decision making. Through its cloud platform, Karooooo empowers businesses to conquer operations including fleet maintenance, fuel management and asset utilization, workforce management, logistics, safety, compliance, risk and environmental impact. Karooooo's differentiated insights and analytics simplify day-to-day operations and enable businesses to decrease costs, increase efficiency, improve safety and strengthen workforce and customer satisfaction. Karooooo is headquartered in Singapore and services more than 125,000 commercial customers and more than 2,300,000 active subscribers in more than 20 countries globally, as of February 28, 2025. View source version on Contacts Media Contactmedia@ Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Monaco: at the Yacht Club, Blumorpho pushes maritime finance forward, 'No time to waste'
MONACO, June 12, 2025 (GLOBE NEWSWIRE) -- The ecological transition of the maritime and port sectors has reached a critical inflection point. In a high-level working session held at the Yacht Club de Monaco, innovation met finance to chart a clear course toward healthier oceans and sustainable infrastructure. The event, led by Blumorpho in partnership with the International Association of Port Cities (AIVP) and supported by the Prince Albert II of Monaco Foundation, brought together port authorities, financial institutions, corporations, and innovators to activate actionable financial mechanisms for the sustainable transformation of coastal urban ecosystems. Part of the momentum building toward the 'Blue Economy Finance Forum' and the UN Ocean Conference (UNOC), the initiative aims to accelerate the deployment of scalable, investable solutions in support of net-zero and biodiversity objectives. Opening the session, Bernard d'Alessandri, General Secretary of the Yacht Club de Monaco, stated: 'On behalf of our President, HSH Prince Albert II, we are pleased to welcome you to the Yacht Club de Monaco to address this key issue. We would like to congratulate the Blumorpho team for their initiative and leadership. On our side, and as part of our collective ambition, 'Monaco, Capital of Advanced Yachting', we are fully committed to advancing sustainable yachting through concrete actions, including the development of the SEA Index®, a tool to assess the carbon footprint of superyachts; and support for pioneering projects through the Monaco Energy Boat Challenge (1–5 July 2025). This commitment is more essential than ever, and we are proud to contribute to the dialogue on how to protect our Ocean.' The day unfolded through expert panels, collaborative workshops, and project showcases, with three core themes emerging: ports as platforms for systemic innovation, strategic capital for climate impact, and concrete, investment-ready projects. Port cities were highlighted as drivers of integrated innovation, connecting clean energy, biodiversity, mobility, and industrial transformation. Financially, new models are gaining traction, from blended finance and blue bonds to private equity and infrastructure debt. Flagship projects from Kribi, Riga, San Diego, Genoa, and Bordeaux showcased pathways that combine decarbonization, aquaculture, digital infrastructure, and inclusive growth. 'The real challenge is not only funding the transition, but designing collaborative and business models that align profitability with long-term climate and societal goals,' explained Géraldine Andrieux, CEO of Blumorpho. Featured case studies included Ineos Energy's integrated approach to carbon capture and storage, and Republic Bank's expanding role in green infrastructure across Caribbean ports and beyond. 'As key players in the globalisation of trade, port cities bear a large share of the responsibility for the climate change. But the richness of their ecosystem means that they are also home to some of the solutions,' said Bruno Delsalle, General Manager of AIVP. The session sets the stage for a shared roadmap to be presented at the AIVP World Conference Cities & Ports 2025, scheduled in New York this November. Tisha Marajh, Group Sustainability Officer at Republic Bank, concluded with a firm call to action: 'We don't have time to waste. We are among the most affected by climate change. Phased investments tailored to attract different kinds of financing can provide a more sustainable path forward. We also need systems to identify small upstream projects, manage ESG risks, and facilitate technology transfer. Sustainable finance is a market opportunity, and we, as financial institutions, are ready to engage, if the right conditions are in place, in Caribbeans and at global scale.' For more information:- A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
